How do Mesoblast’s proprietary Mesenchymal Precursor Cells (MPCs) reduce damaging inflammation and reverse endothelial dysfunction?
Mesoblast’s preclinical studies have shown that MPCs secrete specific factors which convert the pro-inflammatory M1 macrophage to an anti-inflammatory M2 macrophage (a phenomenon termed
macrophage polarization). This results in switching off the production of damaging inflammatory factors.
Cell Therapy News/Articles, page-249
-
- There are more pages in this discussion • 17,781 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
94.5¢ |
Change
-0.025(2.58%) |
Mkt cap ! $1.078B | |||
| Open | High | Low | Value | Volume |
| 98.0¢ | 98.5¢ | 94.0¢ | $2.482M | 2.602M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 71720 | 94.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 94.5¢ | 10463 | 1 |
View Market Depth
| Last trade - 16.10pm 06/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |